Kymera Therapeutics Inc. (KYMR) is looking forward to a strong quarter

Kymera Therapeutics Inc. (NASDAQ: KYMR) stock fell -4.52% on Friday to $32.51 against a previous-day closing price of $34.05. With 1.13 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.74 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $34.51 whereas the lowest price it dropped to was $31.28. The 52-week range on KYMR shows that it touched its highest point at $69.12 and its lowest point at $13.15 during that stretch. It currently has a 1-year price target of $58.79.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of KYMR was up-trending over the past week, with a rise of 15.57%, but this was up by 34.84% over a month. Three-month performance surged to 95.84% while six-month performance fell -24.71%. The stock lost -42.67% in the past year, while it has lost -48.80% so far this year. A look at the trailing 12-month EPS for KYMR yields -2.48 with Next year EPS estimates of -3.21. For the next quarter, that number is -0.70. This implies an EPS growth rate of -70.00% for this year and -16.30% for next year.

Float and Shares Shorts:

At present, 51.65 million KYMR shares are outstanding with a float of 47.90 million shares on hand for trading. On Jul 14, 2022, short shares totaled 6.39 million, which was 12.35% higher than short shares on Jun 14, 2022. In addition to Dr. Bruce L. Booth D.Phil., DPHIL, Ph.D. as the firm’s Co-Founder & Chairman, Dr. Nello Mainolfi M.D., Ph.D. serves as its Co-Founder, Pres, CEO & Director.


Institutional Ownership:

Through their ownership of 96.89% of KYMR’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 38.91% of KYMR, in contrast to 38.37% held by mutual funds. Shares owned by individuals account for 22.54%. As the largest shareholder in KYMR with 10.10% of the stake, T. Rowe Price Associates, Inc. holds 5,224,686 shares worth 5,224,686. A second-largest stockholder of KYMR, BVF Partners LP, holds 4,138,758 shares, controlling over 8.00% of the firm’s shares. Wellington Management Co. LLP is the third largest shareholder in KYMR, holding 3,225,749 shares or 6.24% stake. With a 5.48% stake in KYMR, the SPDR S&P Biotech ETF is the largest stakeholder. A total of 2,835,311 shares are owned by the mutual fund manager. The T Rowe Price New Horizons Fund, which owns about 3.33% of KYMR stock, is the second-largest Mutual Fund holder. It holds 1,720,644 shares valued at 33.88 million. T Rowe Price Small Cap Value Fund holds 1.90% of the stake in KYMR, owning 981,953 shares worth 19.33 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for KYMR since 15 analysts follow the stock currently. There are 11 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 4 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With KYMR analysts setting a high price target of $93.00 and a low target of $26.00, the average target price over the next 12 months is $55.71. Based on these targets, KYMR could surge 186.07% to reach the target high and fall by -20.02% to reach the target low. Reaching the average price target will result in a growth of 71.36% from current levels.


EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. KYMR will report FY 2022 earnings on 03/09/2023. Analysts have provided yearly estimates in a range of -$1.54 being high and -$3.65 being low. For KYMR, this leads to a yearly average estimate of -$2.74. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Kymera Therapeutics Inc. surprised analysts by -$0.09 when it reported -$0.78 EPS against a consensus estimate of -$0.69. The surprise factor in the prior quarter was -$0.04. Based on analyst estimates, the high estimate for the next quarter is -$0.42 and the low estimate is -$1.03. The average estimate for the next quarter is thus -$0.74.

Summary of Insider Activity:

Insiders traded KYMR stock several times over the past three months with 9 Buys and 0 Sells. In these transactions, 299,526 shares were bought while 0 shares were sold. The number of buy transactions has increased to 45 while that of sell transactions has risen to 40 over the past year. The total number of shares bought during that period was 1,343,884 while 286,272 shares were sold.

Leave a Comment

Your email address will not be published.

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]